As mentioned in this review, selected interleukins have been shown to exhibit an only promoting (IL-4, IL-17, IL-21) or exclusively protective (IL-10) role in MS development, with some cytokines being identified as exhibiting both (IL-2, IL-6, IL-13, IL-22, IL-33). This evidence concerns the gene IL17A and myeloid sarcoma.